TIRmed Pharma Strengthens Regulatory Expertise Ahead of Clinical Trials
TIRmed Pharma, a biotechnology company developing innovative treatments for autoimmune skin diseases, has strengthened its regulatory capabilities by recruiting Elisabeth Augustsson, a leading specialist in regulatory affairs. The appointment marks an important step in the preparations for clinical trials of TIR-C, the company’s novel immunomodulatory treatment for atopic dermatitis (eczema).
Elisabeth Augustsson, a seasoned regulatory affairs expert with extensive experience working with both the FDA and EMA, joins TIRmed as a consultant to support the company’s regulatory strategy. Her deep knowledge of international regulatory pathways will be instrumental in advancing TIR-C toward clinical development and future market approval.
“Bringing TIR-C into the clinic is a major milestone for us – and it demands the right team. Elisabeth brings not only extensive experience, but also the strategic mindset we need at this stage. Her contributions will be essential as we move through the regulatory process and prepare for clinical execution,” says Leo Holmgren, CEO of TIRmed Pharma.
The appointment reflects TIRmed’s strong commitment to building the capabilities required for clinical readiness, as the company advances TIR-C toward its first-in-human study.
For more information, please contact:
Leo Holmgren, CEO
Phone: +46 70 049 18 42
Email: leo.holmgren@tirmedpharma.com
About TIRmed Pharma
TIRmed Pharma is a biotechnology company developing next-generation immunomodulatory therapies for autoimmune skin diseases, with an initial focus on Atopic Dermatitis (eczema). Despite being a common condition, current treatments often provide only symptomatic relief. The company’s drug candidate, TIR-C, is a topical oligonucleotide-based treatment that regulates immune responses and targets the disease’s underlying mechanisms rather than just controlling symptoms. Promising preclinical results support its potential to provide long-lasting relief and reduce treatment burden. Building on expertise in immunology and drug development, the company is pioneering new solutions in dermatological immunotherapy to enable more targeted and effective treatment options.
TIRmed Pharma is headquartered in Stockholm, Sweden. For more information, visit tirmedpharma.com and follow TIRmed on LinkedIn.
Tags:
